LONDON & NEW YORK – In a significant stride forward for cancer research, an international consortium of scientists has unveiled a startling connection between the natural process of ageing and aggressive cancer progression. Researchers from the Francis Crick Institute, University College London (UCL), Gustave Roussy, and Memorial Sloan Kettering Cancer Center (MSK) have discovered that the expansion of mutant blood cells, a phenomenon inherently linked to ageing, can infiltrate cancerous tumours. This infiltration, termed tumour infiltrating clonal haematopoiesis (TI-CH), has been definitively associated with worse prognoses for patients across a spectrum of cancer types, irrespective of age or disease stage.
The landmark study, published today in the prestigious New England Journal of Medicine, bridges a critical gap in our understanding of how age-related genetic changes intersect with diseases of ageing, particularly cancer. It illuminates a previously underappreciated mechanism by which the body’s own ageing processes can inadvertently fuel tumour growth and spread, offering profound implications for diagnosis, prognosis, and the development of innovative preventative and therapeutic strategies for a rapidly ageing global population.
Main Facts: A Silent Threat from Ageing Blood
The core discovery centers on a condition known as clonal haematopoiesis of indeterminate potential (CHIP). CHIP describes a scenario where blood stem cells, over time and under the influence of both genetic predisposition and environmental factors, accumulate specific mutations. While often asymptomatic and initially considered "of indeterminate potential," CHIP has been increasingly recognized as a risk factor for various age-related disorders, including cardiovascular disease. However, its direct impact on solid cancer evolution and patient outcomes remained largely unexplored until now.
This new research reveals that when these CHIP-mutated blood cells infiltrate solid tumours, they transform into tumour infiltrating clonal haematopoiesis (TI-CH). The presence of TI-CH, rather than CHIP in the bloodstream alone, is the critical factor linked to a significantly higher risk of cancer relapse and increased cancer mortality. Crucially, this adverse impact was observed across multiple cancer types, including notoriously difficult-to-treat malignancies like lung, head and neck, and pancreatic cancers. The findings underscore a complex interplay where the ageing immune system, through its accumulation of specific mutations, actively contributes to a more aggressive tumour microenvironment, ultimately shortening patient survival.
Chronology: Unravelling the Connection
The journey to this groundbreaking discovery was a meticulous, multi-phase investigation spanning several years and involving extensive patient data.
The Initial Spark: Observing a Correlation
The research commenced with an initial examination of blood samples from over 400 patients with lung cancer, primarily drawn from the Cancer Research UK-funded TRACERx and PEACE studies. The first step involved identifying which of these patients harbored CHIP mutations in their circulating blood. When this genetic information was meticulously matched with comprehensive clinical data, a concerning pattern emerged: patients with CHIP mutations exhibited a statistically significant shorter survival period. This alarming correlation held true even after accounting for other crucial prognostic factors, such as the patient’s age at diagnosis and the stage of their cancer. This initial finding strongly suggested that CHIP was not merely an innocent bystander but an active participant influencing cancer trajectory.
The Pivotal Discovery: Tumour Infiltration (TI-CH)
Recognizing the strong association, the research team then embarked on a deeper investigation. They hypothesized that the impact of CHIP might be more direct, involving the physical presence of these mutant cells within the tumour itself. Through sophisticated genetic sequencing and pathological analysis of tumour biopsies, they meticulously determined whether the specific CHIP mutations identified in the blood were also present within the lung tumours due to the infiltration of blood cells. Their hypothesis proved correct: a substantial 42% of patients with CHIP also showed evidence of these mutations within their tumours. This phenomenon was subsequently christened tumour infiltrating clonal haematopoiesis (TI-CH).
This distinction proved to be a critical turning point. While CHIP in the blood was associated with poorer outcomes, it was the presence of TI-CH – the actual infiltration of these mutant cells into the tumour microenvironment – that was robustly linked to the greater risk of cancer relapse and, tragically, cancer-related death. This finding refined their understanding, pinpointing the direct interaction within the tumour as the key driver of adverse outcomes.
Validating the Infiltration: The PEACE Study Contribution
To further solidify the link between TI-CH and advanced disease, the team turned to samples from the PEACE study. The PEACE study is a unique post-mortem investigation that provides an unparalleled opportunity to analyze metastatic sites – the areas where cancer has spread, which is the primary cause of cancer death. Analysis of these metastatic tumours frequently revealed the presence of TI-CH mutations, lending powerful support to the hypothesis that these infiltrating mutant blood cells play a role in the most aggressive and lethal forms of cancer progression.
Unmasking the Mechanism: Not All Mutations Are Equal
With the "what" firmly established, the researchers then delved into the "how." They sought to understand the biological mechanisms by which TI-CH exerted its detrimental effects. Their investigation into the cellular composition of the lung tumours provided crucial insights. They observed that patients with TI-CH exhibited a significant expansion of myeloid cells, a specific type of immune cell. This was a critical clue, as myeloid cells are known to play a complex and often contradictory role in the tumour microenvironment. Unlike some immune cells that are primed to recognize and destroy cancer cells, myeloid cells have been implicated in regulating inflammation and, crucially, can support tumour progression, angiogenesis (new blood vessel formation), and metastatic spread.
The team then narrowed their focus to specific mutations within the CHIP profile. They discovered that when mutations affected a gene called TET2, which is a vital regulator of blood cell production, these TET2 mutant blood cells were significantly more prone to infiltrating tumours. To confirm the cellular location of these mutations, they employed single-cell sequencing techniques on hundreds of individual cells isolated from the tumours of two patients with TI-CH. This high-resolution analysis definitively showed that TET2 mutations were predominantly present within myeloid cells, rather than other immune cell types, reinforcing the connection between specific mutations, specific cell types, and tumour infiltration.
Experimental Proof: Organoid Models
To move beyond observational data and establish a causal link, the research team collaborated with experts in blood cancer and CHIP at the Crick, led by Dominique Bonnet. Together, they designed elegant experimental models. They grew "organoids" – miniature lung tumours – in a laboratory setting and introduced TET2 mutant myeloid cells into this environment. The results were compelling: the TET2 mutant myeloid cells actively remodelled the tumour microenvironment, creating conditions conducive to accelerated tumour organoid growth. This experimental validation provided strong evidence that these specific mutant blood cells directly contribute to tumour aggressiveness.
Broadening the Scope: Validation Across Cancer Types
Finally, to ascertain the generalizability of their findings, the team collaborated with researchers at Memorial Sloan Kettering Cancer Center (MSK) in the US. They leveraged an immense dataset comprising over 49,000 patients with a diverse array of cancer types. The results from this large-scale validation study were unequivocal: the presence of TI-CH consistently emerged as an independent predictor of shorter overall survival across this vast cohort.
While the adverse impact of TI-CH was broadly observed, the researchers also noted variations in the prevalence of CHIP and TI-CH across different cancer types. Intriguingly, these mutations were found to be more common in cancers that are notoriously harder to treat and have poorer prognoses, such as lung cancer, head and neck cancer, and pancreatic cancer. This further underscores the potential clinical utility of TI-CH as a prognostic biomarker, particularly for these aggressive malignancies.
Supporting Data: Deep Dive into the Biological Interface
The significance of this research lies in its detailed exploration of the "biological interface of age-related genetic changes and diseases of ageing." CHIP, or Clonal Haematopoiesis of Indeterminate Potential, represents a fundamental aspect of biological ageing. It is characterized by the expansion of a single clone of hematopoietic (blood-forming) stem cells that carry specific somatic mutations. These mutations are acquired throughout life, influenced by factors ranging from cumulative DNA damage to chronic inflammation and environmental exposures. While the overall incidence of CHIP increases dramatically with age, affecting over 10% of individuals over 65, its clinical consequences have only recently begun to be fully appreciated. Previously recognized for its association with an increased risk of blood cancers and cardiovascular disease, its role in solid tumour biology had remained a critical blind spot.
The TRACERx (Tracking Cancer Evolution Through therapy) and PEACE (Postmortem Examination of Advanced Cancer Environments) studies, which provided much of the initial patient material, are flagship Cancer Research UK initiatives. TRACERx is a pioneering observational study tracking the evolutionary trajectory of non-small cell lung cancer from diagnosis through treatment and relapse, using multi-region biopsies and advanced sequencing. The PEACE study complements this by offering unparalleled insights into the metastatic landscape of advanced cancers, providing invaluable tissue samples for understanding the mechanisms of cancer spread, the leading cause of death. The integration of data from these highly detailed UK-based studies with the vast clinical database from MSK, one of the world’s leading cancer centers, provided both depth and breadth to the research, bolstering the statistical power and generalizability of the findings.
The mechanism involving myeloid cells is particularly compelling. The tumour microenvironment (TME) is a complex ecosystem comprising cancer cells, stromal cells, blood vessels, and a diverse array of immune cells. Myeloid cells, which include macrophages, neutrophils, and myeloid-derived suppressor cells (MDSCs), are crucial components of the innate immune system. In a healthy context, they play vital roles in tissue repair and host defense. However, within the TME, they often become "re-educated" by the tumour to adopt pro-tumourigenic functions. They can promote chronic inflammation, suppress anti-tumour immune responses, remodel the extracellular matrix to facilitate invasion, and secrete growth factors that support tumour cell proliferation and angiogenesis. The finding that TET2-mutant myeloid cells specifically expand and infiltrate tumours, then actively accelerate tumour growth, provides a clear molecular and cellular pathway for CHIP’s detrimental effects.
The TET2 gene (Ten-Eleven Translocation 2) is a key epigenetic regulator. It encodes an enzyme that plays a critical role in DNA demethylation, a process essential for normal gene expression and cell differentiation, particularly in hematopoietic stem cells. Mutations in TET2 are among the most common alterations found in CHIP and are also frequently observed in myeloid blood cancers such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The fact that TET2 mutations within myeloid cells are specifically implicated in TI-CH and tumour acceleration highlights the precise molecular pathways through which age-related changes can be hijacked by cancer.
The variation in CHIP and TI-CH prevalence across different cancer types is also noteworthy. The observation that these mutations are more common in aggressive cancers like lung, head and neck, and pancreatic cancer suggests that TI-CH might be a particularly potent contributor to the poor outcomes associated with these malignancies, or that the specific microenvironments of these tumours are more permissive to the infiltration and pro-tumourigenic activity of mutant myeloid cells. Further research will be needed to elucidate these tissue-specific interactions.
Official Responses: Voices from the Frontier
The researchers involved in this monumental study underscored the immediate and future implications of their findings.
Oriol Pich, Postdoctoral Project Research Scientist in the Crick’s Cancer Evolution and Genome Instability Laboratory, emphasized the direct impact of the discovery: "Our results show that blood cells carrying age-related mutations can infiltrate tumours and impact cancer evolution, leading to worse outcomes for patients. This is important because CHIP is a natural phenomenon of ageing that is common in patients with cancer." Pich’s statement highlights the pervasive nature of CHIP in an ageing population and its previously unrecognized role in exacerbating cancer severity.
Professor Charlie Swanton, Deputy Clinical Director at the Crick, Chief Clinician at Cancer Research UK, and Chief Investigator for TRACERx, spoke to the unprecedented scale and novelty of the research: "This is the first time that we’ve been able to see at scale, the interaction of two different types of ‘clonal proliferations,’ age-related CHIP and cancer, providing insight into how ageing might impact cancer risk. As we start to piece together the picture of the most important mutations which evolve during the ageing process in cells from the bone marrow, and the impact they have in disease, we hope we can start to identify opportunities for intervention and maybe even prevention of some age-related cancers." Professor Swanton’s perspective points towards a paradigm shift, viewing CHIP not just as a risk for blood disorders but as a crucial factor in the broader landscape of age-related cancer development and progression. His vision of identifying opportunities for intervention and prevention underscores the translational potential of this discovery.
This extensive and collaborative work was made possible through significant financial backing from key organizations, including Cancer Research UK and the National Institute of Health and Care Research UCLH Biomedical Research Centre, alongside additional funders, reflecting the strategic importance of this area of research.
Implications: Paving the Way for a New Era in Cancer Management
The discovery of TI-CH and its profound impact on cancer outcomes carries wide-ranging implications, promising to reshape future research directions, clinical practice, and public health strategies.
1. Novel Prognostic Biomarker: The most immediate clinical application is the potential for TI-CH to serve as a powerful new prognostic biomarker. Identifying TI-CH in cancer patients could allow clinicians to more accurately stratify risk, identifying those at highest risk of relapse and mortality. This improved risk stratification could inform more aggressive treatment strategies, closer monitoring, or enrollment in clinical trials for novel therapies. For instance, in patients with lung, head and neck, or pancreatic cancer, where TI-CH is more prevalent, its detection could be a crucial factor in treatment planning.
2. Therapeutic Targets and Interventions: The identification of TET2 mutations in myeloid cells as a key driver of TI-CH-mediated tumour progression opens up new avenues for therapeutic intervention. Strategies aimed at modulating the activity of TET2-mutant myeloid cells, or the inflammatory pathways they activate within the tumour microenvironment, could potentially slow tumour growth, reduce metastasis, and improve patient survival. This could involve repurposing existing drugs or developing novel agents specifically targeting these cellular pathways. Immunotherapies that aim to re-educate or deplete pro-tumourigenic myeloid cells are already a focus in oncology, and this research provides a strong rationale for their application in TI-CH positive patients.
3. Preventative Strategies for Age-Related Cancers: Professor Swanton’s vision of "prevention of some age-related cancers" is particularly exciting. If CHIP, and subsequently TI-CH, is a significant driver of aggressive cancer, then interventions that prevent the development or expansion of CHIP clones, or mitigate their pro-tumourigenic effects, could become a cornerstone of cancer prevention in older populations. This might involve lifestyle modifications, anti-inflammatory agents, or even targeted therapies to suppress problematic CHIP clones before they can infiltrate tumours.
4. Redefining the Cancer-Ageing Interface: This research fundamentally alters our understanding of the relationship between ageing and cancer. It moves beyond the idea that ageing simply increases the risk of cancer by accumulating mutations in somatic cells; instead, it demonstrates that age-related changes in the immune system itself can actively drive cancer aggressiveness. This integrated view of ageing biology and oncology will stimulate new research into the systemic effects of ageing on tumour evolution and the role of the ageing immune system in shaping cancer outcomes.
5. Personalised Medicine: The ability to detect CHIP and TI-CH mutations through relatively straightforward blood and tumour biopsies aligns perfectly with the principles of personalised medicine. Future clinical protocols could involve routine screening for CHIP in cancer patients, and potentially even in healthy older individuals at high risk, to tailor preventative or therapeutic strategies.
Next Steps for Research:
While the findings are robust, the researchers acknowledge that further work is essential. The immediate next steps include:
- Confirming Direct Causation: Rigorous experimental studies are needed to unequivocally confirm that CHIP directly contributes to cancer outcomes across various models, solidifying the causal link observed in patient data.
- Detailed Mechanistic Elucidation: A deeper dive into the exact molecular and cellular mechanisms by which CHIP functionally implicates the development of aggressive cancers is required. This would involve comprehensive proteomic, transcriptomic, and epigenetic analyses to unravel the complex signaling pathways involved.
- Longitudinal Studies: Following large cohorts of CHIP-positive individuals over time will be crucial to understand the natural history of TI-CH development and its progression in different cancer types.
In conclusion, this landmark study represents a pivotal moment in oncology. By demonstrating how the subtle, age-related changes in our blood cells can turn into formidable allies for cancer, the research team has not only provided critical prognostic insights but also illuminated new pathways for therapeutic innovation. As the global population continues to age, understanding and combating these intertwined mechanisms of ageing and cancer will be paramount to improving human health and extending healthy lifespans. The future of cancer care may well lie in understanding and intervening with the ‘ageing’ within us.
About the Author
